Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimodulin add-on therapy for severe COVID-19
2020-002345-42Phase 2Completed
- Sponsor
- Biotest AG
- Start
- Jul 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia comparing Trimodulin + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Composite endpoint. Started Jul 2020; status: completed.
02
Drugs
Pentaglobin
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-002345-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002345-42.